McGill Mitchell R, Curry Steven C
Dept. of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR 72212, USA.
Dept. of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72212, USA.
Livers. 2023 Dec;3(4):569-596. doi: 10.3390/livers3040039. Epub 2023 Oct 27.
Acetaminophen (APAP) is a widely used drug, but overdose can cause severe acute liver injury. The first reports of APAP hepatotoxicity in humans were published in 1966, shortly after the development of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as the first biomarkers of liver injury as opposed to liver function. Thus, the field of liver injury biomarkers has evolved alongside the growth in APAP hepatotoxicity incidence. Numerous biomarkers have been proposed for use in the management of APAP overdose patients in the intervening years. Here, we comprehensively review the development of these markers from the 1960s to the present day and briefly discuss possible future directions.
对乙酰氨基酚（APAP）是一种广泛使用的药物，但过量服用会导致严重的急性肝损伤。1966年，人类首次报告了APAP肝毒性，当时谷丙转氨酶（ALT）和谷草转氨酶（AST）作为肝损伤而非肝功能的首批生物标志物刚出现不久。因此，肝损伤生物标志物领域随着APAP肝毒性发病率的增长而发展。在这期间，人们提出了许多生物标志物用于管理APAP过量服用的患者。在此，我们全面回顾了这些标志物从20世纪60年代至今的发展历程，并简要讨论了未来可能的发展方向。
